Emergent BioSolutions revealed this week plans to expand its viral vector and gene therapy capabilities.
The company announced it will invest $75 million in its Canton, Mass., facility, which is focused on the contract development and manufacturing (CDMO) of drug substances for live viral vaccines, including the company’s smallpox vaccine
{iframe}https://homelandprepnews.com/stories/51062-emergent-biosolutions-invests-75m-in-viral-vector-gene-therapy-capabilities/?amp{/iframe}